Skip to main content
SpringerLink
Log in

Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

An Erratum to this article was published on 02 November 2010

An Erratum to this article was published on 02 November 2010

Abstract

Introduction

This pooled analysis of data from three phase 3 studies in patients with chronic osteoarthritis knee or low back pain evaluated the efficacy and tolerability of tapentadol prolonged release (PR; 100–250 mg twice daily) compared with placebo and oxycodone hydrochloride (HCl) controlled release (CR; 20–50 mg twice daily).

Methods

Patients in each study were randomized to receive twice-daily doses of placebo, tapentadol PR (100–250 mg), or oxycodone HCl CR (20–50 mg) for a 12-week maintenance period, preceded by a 3-week titration period. Primary endpoints were change from baseline in average pain intensity (11-point numeric rating scale) at week 12 of the maintenance period and for the overall maintenance period using last observation carried forward for imputation of values missing after treatment discontinuation.

Results

A total of 2968 patients were evaluated for efficacy; 2974 patients were evaluated for safety. Compared with placebo, treatment with tapentadol PR or oxycodone CR resulted in significantly greater reductions in pain intensity from baseline at week 12 and for the overall maintenance period (all P<0.001). For both primary endpoints, the efficacy of tapentadol PR was noninferior to oxycodone CR (P<0.001), and tapentadol PR had superior gastrointestinal tolerability compared with oxycodone CR (P<0.001). Results of analyses of responders, patient global impression of change, Short Form-36 domains (except general health), and the EuroQol 5-Dimension health status index were significantly better for tapentadol PR than oxycodone CR (all P≤0.048); these results may have been affected by the worse tolerability profile of oxycodone CR. A higher percentage of patients discontinued treatment with oxycodone CR (61.7% [616/999]) compared with tapentadol PR (43.5% [425/978]).

Conclusion

Tapentadol PR (100-250 mg twice daily) was efficacious and provided efficacy that was similar to oxycodone HCl CR (20–50 mg twice daily) for the management of chronic osteoarthritis knee and low back pain, with a superior gastrointestinal tolerability profile and fewer treatment discontinuations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179–183.

    Article  CAS  PubMed  Google Scholar 

  2. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6:21–28.

    Article  CAS  PubMed  Google Scholar 

  3. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23:117–128.

    Article  CAS  PubMed  Google Scholar 

  4. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299.

    Article  PubMed  Google Scholar 

  5. Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006;2:155–166.

    PubMed  Google Scholar 

  6. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29:874–888.

    Article  CAS  PubMed  Google Scholar 

  7. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6:357–366.

    Article  PubMed  Google Scholar 

  8. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160:853–860.

    Article  CAS  PubMed  Google Scholar 

  9. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.

    Article  CAS  PubMed  Google Scholar 

  10. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(Suppl.):S105–S120.

    PubMed  Google Scholar 

  11. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.

    Article  PubMed  Google Scholar 

  12. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–276.

    Article  CAS  PubMed  Google Scholar 

  13. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl. Drugs Future. 2006;31:1053–1061.

    Article  CAS  Google Scholar 

  14. Afilalo M, Kuperwasser B, Kelly K, et al. Efficacy and safety of tapentadol extended release (ER) for chronic pain due to osteoarthritis of the knee: results of a phase 3 study. Pain Pract. 2009;9:159.

    Google Scholar 

  15. Buynak R, Shapiro D, Okamoto A, Lange C, Etropolski M. Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain. J Pain. 2009;10:S48.

    Article  Google Scholar 

  16. Ware JE, Jr., Donald Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.

    Article  PubMed  Google Scholar 

  17. The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.

    Article  Google Scholar 

  18. Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the ‘gold standard’ design. Biom J. 2005;47:782–786.

    Article  PubMed  Google Scholar 

  19. Wild JE, Grond S, Kuperwasser B, et al. Longterm safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. In press.

  20. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005;21:524–535.

    Article  PubMed  Google Scholar 

  21. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26:862–869.

    CAS  PubMed  Google Scholar 

  22. Purdue Pharma. Oxycontin® (oxycodone HCl controlled-release) product. Stamford, CT: Purdue Pharma L.P.; 2007.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Development, Grünenthal GmbH, Zieglerstrasse 6, Bldg 609, D-52078, Aachen, Germany

    Bernd Lange, Achim Steup, Thomas Häufel & Judy Ashworth

  2. Johnson & Johnson Pharmaceutical Research & Development, Titusville, New Jersey, USA

    Brigitte Kuperwasser, Akiko Okamoto & Mila Etropolski

Authors
  1. Bernd Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brigitte Kuperwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Achim Steup
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Häufel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Judy Ashworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mila Etropolski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Lange.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s12325-010-0086-6

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lange, B., Kuperwasser, B., Okamoto, A. et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Therapy 27, 381–399 (2010). https://doi.org/10.1007/s12325-010-0036-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0036-3

Keywords

Search

Navigation